A randomized Phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants

A randomized Phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants

Objectives: To assess the safety and reactogenicity of single oral dose of heat-stable rotavirus vaccine (HSRV) in healthy adults aged 18–45 years followed by assessment of safety, reactogenicity, and immunogenicity of three doses of HSRV in healthy infants aged 6–8 weeks at enrollment. Trial Design...

Full description

Bibliographic Details
Main Authors: Vibhu Kanchan, Khalequ Zaman, Asma Binte Aziz, Sheikh Farzana Zaman, Farzana Zaman, Warda Haque, Mahbuba Khanam, Mohammad Mahbubul Karim, Sachin Kale, Syed Khalid Ali, Michelle G. Goveia, Susan S. Kaplan, Davinder Gill, Wasif Ali Khan, Mohammad Yunus, Ajitpal Singh, John D. Clemens
Format: Article
Language:English
Published: Taylor & Francis Group 2020-03-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
heat stable rotavirus vaccine
randomized
safety
reactogenicity
immunogenicity
Online Access:http://dx.doi.org/10.1080/21645515.2019.1664239

Internet

http://dx.doi.org/10.1080/21645515.2019.1664239

Similar Items